Lyell Immunopharma (LYEL) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 4.1% versus a loss of 51.6%. Entrada Therapeutics is the larger company by market cap ($210.5 million vs $204.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYEL | TRDA |
|---|---|---|
| Share price | $8.33 | $5.41 |
| Market cap | $204.01M | $210.45M |
| 1-day change | -2.75% | -3.65% |
| YTD return | -72.19% | -45.43% |
| 1-year return | -51.61% | -4.10% |
| 5-year return | -96.78% | — |
| EPS (TTM) | $-12.86 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.00 | $16.45 |
| 52-week low | $8.28 | $5.15 |
| Distance from 52-week high | -81.50% | -67.14% |
| Analyst consensus | buy | none |
| Avg. price target upside | +355.02% | +251.53% |
| Average volume | 144.81K | 359.01K |
| Shares outstanding | 24.51M | 38.94M |
| Employees | 161 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed LYEL by 47.5 percentage points over the past year.
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
LYEL vs TRDA FAQ
Which is bigger, Lyell Immunopharma or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $210.45M compared with $204.01M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, LYEL or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -51.61% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Lyell Immunopharma and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.